ESTRELLA IMMUNOPHARMA, INC. Cash and Restricted Cash
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Cash and Restricted Cash of $146.67 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $146.67K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.93M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.38M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $146.67K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.93M 10-Q · filed 2026-05-18 | |
| 2025-12-31 | $1.38M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $1.63M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $1.32M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $421.47K 10-Q · filed 2026-05-18 | |
| 2024-12-31 | $916.92K 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $1.80M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $4.17M 10-K · filed 2026-03-18 | |
| 2024-03-31 | $4.73M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $9.05M 10-Q · filed 2025-11-12 | |
| 2023-09-30 | $22.14M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $2.48M 10-KT · filed 2025-03-25 | $34.69K 10-Q · filed 2023-08-01 |
| 2023-03-31 | $2.66M 10-Q · filed 2024-05-15 | $29.39K 10-Q · filed 2023-05-18 |
| 2022-12-31 | $2.88M 10-Q · filed 2024-02-14 | $40.80K 10-K · filed 2023-03-14 |
| 2022-09-30 | $2.99M 10-Q · filed 2023-11-20 | $73.75K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.09M 10-K · filed 2024-09-27 | $88.28K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $321.72K 10-Q · filed 2023-05-18 | |
| 2021-12-31 | $478.87K 10-Q · filed 2023-08-01 | |
| 2021-09-30 | $772.17K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $11.02K 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $42.08K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |